Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Shrinking team NBB
FTE fell two years in a row, from 25.2 to 0.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
-
Legal situation KBO
Vrijwillige ontbinding – vereffening according to the CBE.
Financials
Financial year 2025
Cellaïon from Mont-Saint-Guibert, company number BE0764522425, closed financial year 2025 with a result of € -15,747 after tax. For that financial year Cellaïon recorded a gross margin of € -25,151 and equity of € -13.9 million. Compared with financial year 2024, the result moved from € -7.7 million to € -15,747. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 25, 2026.
€ -13.9 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -15,747
▲ 100 % less loss than in 2024
Profit after tax over the fiscal year.
€ 1.4 million
▲ 12% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -21 million.
People and assets in 2025
0
▼ 15.5 vs 2024
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
€ 7.6 million
Loans from banks and other lenders, long and short.
€ 2.5 million
▼ 2% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -6,078,669 | € -6,590,813 | € -4,029,044 | € -25,151 | ▲ € 4 million |
| Profit after taxes | € -9,394,008 | € -13,234,046 | € -7,708,289 | € -15,747 | ▲ € 7.7 million |
| Equity | € 1,048,079 | € -6,142,063 | € -13,847,585 | € -13,863,332 | |
| Total debts | € 10,876,108 | € 11,558,280 | € 15,102,118 | € 15,059,896 | |
| Cash | € 8,298,056 | € 2,883,660 | € 1,248,036 | € 1,393,596 | ▲ 12% |
| Retained profit | € -15,038,521 | € -13,234,046 | € -20,942,335 | € -20,958,082 | |
| Bank debt | € 3,575,000 | € 3,500,000 | € 7,612,642 | € 7,612,642 | |
| Balance sheet total | € 12,376,353 | € 7,487,085 | € 2,335,377 | € 2,277,408 | ▼ 2% |
| Employees (FTE) | 23.6 | 25.2 | 15.5 | 0 | ▼ 15.5 |
Key figures of Cellaïon, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Cellaïon?
What happened at Cellaïon in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
Cellaïon is active according to the CBE. Legal situation: Vrijwillige ontbinding – vereffening.
- New annual accounts for financial year 2025: loss of € 15,747. Source: NBB ↗
- Cédric ALTER became a director. NBB
- New establishment in Mont-Saint-Guibert. KBO
- Start of the company according to the CBE. KBO
In short
From € 9.4 million loss in 2022 to € 15,747 loss in 2025.
Paid € 10,854 in corporate taxes since 2022.
A new publication or filing at Cellaïon? We notify you, reason included.
Follow CellaïonDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Newton Biocapital II, Wallonie Entreprendre, Fund+, SOPARTEC comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
CellaïonBehind Cellaïon is Cédric ALTER. The shares are held by Newton Biocapital II (16.9%), Wallonie Entreprendre (16.2%), Fund+ (0.9%) and SOPARTEC (0.4%).
Directors
According to the 2025 annual accounts
Cédric ALTER
Liquidator
since 2024
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Granbonpré 11
1435 Mont-Saint-Guibert
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →DE SMET AGRO
€ 8.7 million revenue · 2025
DE SMET S.A. - ENGINEERS & CONTRACTORS
€ 31.8 million revenue · 2025
CEDRIC CLAERHOUDT
€ 937,969 gross margin · 2024
Tools4Patient
€ -431,027 gross margin · 2025
NOVADIP BIOSCIENCES
€ 1.6 million gross margin · 2025
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0764.522.425
- VAT number
- BE 0764.522.425
- Registered office
- Rue Granbonpré 11, 1435 Mont-Saint-Guibert
- Names & denominations
- Cellaïon
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Vrijwillige ontbinding – vereffening
- Start date
- 2 March 2021
- Peppol
- Not registered
- Contact
- promethera.com [email protected]
- Activities · NACE
Activiteiten op het gebied van voeding
Overige menselijke gezondheidszorg, n.e.g.
Speur- en ontwikkelingswerk op biotechnologisch gebied